dc.contributor
Institut Català de la Salut
dc.contributor
[Herrera M, Siu LL] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. [Pretelli G] Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Desai J] Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. [Garralda E] Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Steiner TM] Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Herrera, Mercedes
dc.contributor.author
M. Steiner, Thiago
dc.contributor.author
Pretelli, Giulia
dc.contributor.author
Desai, Jayesh
dc.contributor.author
GARRALDA, Elena
dc.contributor.author
Siu, Lillian
dc.date.accessioned
2025-02-11T04:18:33Z
dc.date.available
2025-02-11T04:18:33Z
dc.date.issued
2025-02-10T12:12:08Z
dc.date.issued
2025-02-10T12:12:08Z
dc.identifier
Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, et al. Bispecific antibodies: advancing precision oncology. Trends in Cancer. 2024 Oct;10(10):893-919.
dc.identifier
https://hdl.handle.net/11351/12573
dc.identifier
10.1016/j.trecan.2024.07.002
dc.identifier
001332577000001
dc.identifier.uri
https://hdl.handle.net/11351/12573
dc.description.abstract
T cell engagers; Bispecific antibodies; Immunotherapy
dc.description.abstract
Activadores de células T; Anticuerpos biespecíficos; Inmunoterapia
dc.description.abstract
Activadors de cèl·lules T; Anticossos biespecífics; Immunoteràpia
dc.description.abstract
Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets and structure (or format), which can be manipulated to create variable and novel functionalities, including linking immune cells with tumor cells, or dual signaling pathway blockade. Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to these agents are understudied and the management of toxicities remains challenging. Herein, we review the principles in bsAb engineering, current understanding of mechanisms of action and resistance, data for clinical application, and provide a perspective on ongoing challenges and future developments in this field.
dc.description.abstract
We thank Alan Russell and Michael Dickinson for their helpful suggestions and review of the manuscript. M.H is supported by a Sociedad Española de Oncología Médica (SEOM) fellowship and CRIS Cancer Out-Back program; G.P is supported by the CaixaResearch Advanced Oncology Research Program supported by ‘la Caixa’ Foundation (LCF/PR/CE07/50610001); E.G is supported by the CaixaResearch Advanced Oncology Research Program supported by ‘la Caixa’ Foundation (LCF/PR/CE07/50610001); L.L.S holds the BMO Chair in Precision Cancer Genomics; T.M.S. is funded through a collaboration with Roche; L.A. is supported by the Peter Mac Foundation Discovery Partner Fellowship.
dc.format
application/pdf
dc.relation
Trends in Cancer;10(10)
dc.relation
https://doi.org/10.1016/j.trecan.2024.07.002
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Càncer - Immunoteràpia
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
Medicina personalitzada
dc.subject
Resistència als medicaments
dc.subject
DISEASES::Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Bispecific
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
dc.subject
ENFERMEDADES::neoplasias
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
dc.title
Bispecific antibodies: advancing precision oncology
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
